- Home
- BANX vs VOR Comparison
BANX vs VOR Comparison
Compare BANX & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANX
- VOR
- Stock Information
- Founded
- BANX 2013
- VOR 2015
- Country
- BANX United States
- VOR United States
- Employees
- BANX N/A
- VOR N/A
- Industry
- BANX Trusts Except Educational Religious and Charitable
- VOR Biotechnology: Pharmaceutical Preparations
- Sector
- BANX Finance
- VOR Health Care
- Exchange
- BANX Nasdaq
- VOR Nasdaq
- Market Cap
- BANX 149.0M
- VOR 134.8M
- IPO Year
- BANX N/A
- VOR 2021
- Fundamental
- Price
- BANX $21.08
- VOR $0.90
- Analyst Decision
- BANX
- VOR Strong Buy
- Analyst Count
- BANX 0
- VOR 7
- Target Price
- BANX N/A
- VOR $11.36
- AVG Volume (30 Days)
- BANX 18.7K
- VOR 350.3K
- Earning Date
- BANX 03-25-2025
- VOR 05-08-2025
- Dividend Yield
- BANX 10.04%
- VOR N/A
- EPS Growth
- BANX N/A
- VOR N/A
- EPS
- BANX 2.35
- VOR N/A
- Revenue
- BANX $29,467,794.00
- VOR N/A
- Revenue This Year
- BANX N/A
- VOR N/A
- Revenue Next Year
- BANX N/A
- VOR N/A
- P/E Ratio
- BANX $8.90
- VOR N/A
- Revenue Growth
- BANX 2.74
- VOR N/A
- 52 Week Low
- BANX $17.91
- VOR $0.63
- 52 Week High
- BANX $21.67
- VOR $2.43
- Technical
- Relative Strength Index (RSI)
- BANX 49.56
- VOR 35.85
- Support Level
- BANX $20.80
- VOR $0.81
- Resistance Level
- BANX $21.31
- VOR $0.93
- Average True Range (ATR)
- BANX 0.26
- VOR 0.11
- MACD
- BANX -0.01
- VOR -0.02
- Stochastic Oscillator
- BANX 51.85
- VOR 15.36
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds, and others.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.